Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia

MLA

Gabor Mikala, et al. “Nucleophosmin1 and Isocitrate Dehydrogenase 1 and 2 as Measurable Residual Disease Markers in Acute Myeloid Leukemia.” PLoS ONE, vol. 16, no. 6, Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d15c858d6f1cda383dac1b58e2e20eda&authtype=sso&custid=ns315887.

APA

Gabor Mikala, András Kozma, Ágnes Király, Péter Reményi, Hajnalka Andrikovics, András Bors, István Vályi-Nagy, Petra Kövy, János Dolgos, Viktor Lakatos, László Gopcsa, Zoltán Őrfi, Nóra Lovas, & József Harasztdombi. (2021). Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS ONE, 16(6).

Chicago

Gabor Mikala, András Kozma, Ágnes Király, Péter Reményi, Hajnalka Andrikovics, András Bors, István Vályi-Nagy, et al. 2021. “Nucleophosmin1 and Isocitrate Dehydrogenase 1 and 2 as Measurable Residual Disease Markers in Acute Myeloid Leukemia.” PLoS ONE 16 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d15c858d6f1cda383dac1b58e2e20eda&authtype=sso&custid=ns315887.